Loading
A phase 1/2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer is a phase 1/2 interventional study registered as NCT05316155 by Janssen Research & Development, LLC, with 235 participants enrolled, started 2022-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: Erdafitinib Intravesical Delivery System.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Small-molecule kinase inhibitors and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/